Table 1. Patient's characteristics.
| Categorical data | ||
| Variables | Development dataset 429 cases (%) | Validation dataset 409 Cases (%) |
| Men | 296 (68) | 203 (49) |
| Women | 133 (32) | 206 (51) |
| PS = 0 | 141 (33) | 57 (14) |
| PS = 1 | 138 (32) | 129 (31) |
| PS = 2 | 108 (25) | 103 (25) |
| PS = 3 | 35 (9) | 93 (23) |
| PS = 4 | 4 (1) | 26 (7) |
| Absence of co-morbidity or co- morbidity not requiring treatment | 241 (56) | 264 (66) |
| At least 1 co-morbidity requiring treatment | 172 (44) | 141 (34) |
| Number of met. site = 1 | 168 (39) | 184 (45) |
| Number of met. site = 2 | 107 (25) | 130 (31) |
| Number of met. site = 3 | 85 (20) | 59 (14) |
| Number of met. site = 4 | 43 (10) | 23 (7) |
| Number of met. site≥5 | 26 (6) | 13 (3) |
| Adenocarcinoma | 272 (63) | 210 (51) |
| Undifferentiated carcinoma | 58 (13) | 138 (34) |
| Squamous cell carcinoma | 77 (18) | 24 (6) |
| Others | 22 (6) | 37 (9) |
| Lung met. | 103 (24) | 88 (21) |
| Liver met. | 144 (33) | 174 (42) |
| Bone met. | 156 (36) | 117 (28) |
| Brain met. | 32 (8) | 1 (0) |
| Continuous | ||
| Variables (units) | Development dataset Median (range) | Validation dataset Median (range) |
| Age (years) | 59 (22–91) | 65 (19–92) |
| LDH (IU/l) | 660 (57–10,084) | 428 (86–7,538) |
| Alkaline phosphatase (IU/l) | 280 (31–7,423) | Not done |
| Hemoglobin level (g/dl) | 12.5 (6–17,3) | 12.3 (6–18.2) |
| Platelets (U/mm3) | 320,000 (7,000–830,000) | 374,000 (10,000–736,000) |
| Lymphocytes (U/mm3) | 1,300 (220–6,830) | 1,250 (100–99,2000) |
| Variables | Development dataset 429 cases (%) | Validation dataset Cases (%) |
| Protein levels (g/l) | 68 (49–92) | 69 (42–87) |
| Albumin levels (g/l) | 32 (14–51) | 36 (19–49) |
Abbreviations: PS = performance status, met. = metastasis, LDH = lactate dehydrogenase, ULN = upper limit of normal, IU: international unit, U:unit.